Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Mar 21, 2013- Companies to Provide Open Access to Information with Goal of Accelerating Discovery of Medicines for People Living with Difficult-to-Treat Cancers -
H3 Biomedicine Inc., a biopharmaceutical company specializing in the discovery and development of oncology treatments, and BGI,...
-
Feb 21, 2013
Woodcliff Lake, NJ and Montreal, Quebec, February 21, 2013 - Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., and Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX)...
-
Feb 14, 2013
Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its investigational drug...
-
Jan 10, 2013
Morphotek(®) Inc., a wholly-owned subsidiary of Eisai Inc., announced today top-line results from a Phase III study of its investigational agent...
-
Dec 19, 2012- Companies Pledge to Make Results Publicly Accessible in an Effort to Accelerate Cancer Drug Development -
H3 Biomedicine Inc., a biopharmaceutical company specializing in the discovery and development of oncology treatments, announced today that it has...
-
Dec 17, 2012
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced that it has entered into a definitive asset...
-
Dec 7, 2012
Results from the first large, global Phase III study of Halaven(®) (eribulin mesylate) Injection in patients with early-stage metastatic breast cancer...
-
Nov 28, 2012
Eisai Inc. announced today that six abstracts highlighting new study results will be presented during the 2012 CTRC-AACR San Antonio Breast...
-
Nov 12, 2012
Morphotek(® )Inc., a subsidiary of Eisai Inc., announced today that the United States Food and Drug Administration (FDA) has granted orphan drug...
-
Oct 4, 2012H3 Biomedicine is first partner for program aimed at generating 'first-in-class' patient-relevant targets based on synthetic lethality screens
Horizon Discovery Ltd (Horizon), a leading provider of research tools to support the development of personalized medicines,...